(American Health Newswire) -- There has been controversy over the effectiveness of magnesium treatment for preventing poor outcomes in those who have had a hemorrhagic stroke. After an international randomized trial and meta-analysis, the controversy could end.

"Intravenous magnesium does not affect outcome after aneurysmal subarachnoid hemorrhage. Subgroup analyses did not identify a subgroup of patients who might benefit from magnesium treatment...therefore routine administration of magnesium cannot be recommended," the study authors were quoted as saying.

Around a third of patients with aneurysmal subarachnoid hemorrhage (SAH; the bursting of a blood vessel on the surface of the brain), the deadliest form of stroke, will die within the first month. 20% of those that survive are left disabled. One of the important causes of poor outcome, delayed cerebral ischemia, can occur 4 to 10 days after SAH.

Although there were promising findings from earlier research, recent studies report conflicting results.

In a randomized trial comparing magnesium treatment (606 patients) with a saline placebo (597 patients) conducted in adults with SAH from the Netherlands, Scotland, and Chile, no difference in poor outcome was measured on the modified Rankin Scale between the groups at 3 months. 158 patients (26.2%) given magnesium compared with 151 (25.3%) given placebo had poor outcome.

A further meta-analysis of seven randomized trials that analyzed over 2000 SAH patients also found that magnesium was not superior to placebo.

"The results, although disappointing, are nonetheless very pertinent to the management of patients with aneurysmal subarachnoid hemorrhage. We agree with the researchers, and previous findings, that routine intravenous magnesium sulphate infusion cannot be recommended for patients with aneurysmal subarachnoid hemorrhage," Chethan Venkatasubba Rao and Jose Suarez from Baylor College of Medicine, Texas, USA, were quoted as saying.

SOURCE: Lancet, May 2012

ORLANDO, Fla. (American Health Newswire) --Creams, compression garments, even coffee grinds! According to Dr. Roger Bassin, 80 percent of women past puberty have cellulite and many have tried just about everything to get rid of it. Now just in time for swimsuit season, we'll show you a new FDA approved device that can zap it away in minutes.

What do hail damage, cottage cheese and orange peel have in common? They're all slang for cellulite.

"It's just very frustrating," Pam told American Health

"I was just always self-conscious of it," Kate said.

Kate and Pam say the bumps and lumps on the back of their thighs are always in the back of their minds. When they hit the shore...

"Usually I cover up," Pam said.

"I was the mommy on the beach with a skirt on the whole time," Kate added.

They've spent thousands on treatments and gimmicks, but nothing's worked. They hope a new laser treatment will.

"This is something we've been waiting a long time for," Dr. Roger Bassin, a cosmetic surgeon told American Health.

Dr. Bassin says Cellulaze, which was recently approved by the FDA, uses a laser to do three things. It melts fat just under the skin, cuts the bands that cause the bulges and gets the skin to thicken and tighten. Pam underwent the one-hour treatment.

"You don't even feel like he's doing anything," Pam said

Kate had the procedure a month earlier. Three weeks later...

"The little bits that were all lumpy and bumpy have all smoothened out," Kate said.

Results of a two-year study show Cellulaze increases skin thickness and elasticity. Dr. Bassin says the trial also showed there was no recurrence of cellulite after two years. That's why he believes it's a permanent solution.

"I'm excited not to wear a sarong all summer," Kate said.

"I'm definitely wearing my bikini, I will not cover up!" Pam concluded.

Dr. Bassin says costs for Cellulaze vary by region, but you'll probably pay $2.500 to $3,000 per zone. So if you get the front, side, and rear of your thighs done, you're looking at $7,500 to $9,000.